/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced
today the appointment of J. Michael French as the new President of its U.S.
subsidiary, Rosetta Genomics, Inc.
Mr. French brings to Rosetta seventeen years of business and
operational experience in both the pharmaceutical and biotechnology
industries most recently as Senior Vice President, Corporate Development at
Sirna Therapeutics, Inc. At Sirna, Mr. French was responsible for Sirna's
corporate development activities, including partnerships, collaborations,
product licensing, and mergers and acquisitions. In his eighteen months at
Sirna, the company established two major pharmaceutical collaborations and
was acquired by Merck & Co in December 2006 for $1.1 billion.
"Rosetta has significant potential and now requires a solid,
experienced and innovative management team to take us to the next level,"
stated Amir Avniel, Rosetta CEO. "Michael brings to Rosetta the expertise
and leadership to build that team and advance our technology in multiple
areas. We believe his accomplishments in negotiating and closing high value
strategic alliances as well as his ability to establish strong investor
relationships will be instrumental to our success. We are very pleased to
have Michael join us at Rosetta."
"Rosetta is a cutting-edge biotechnology company with tremendous
opportunity," said Michael French. "I am extremely excited to be a part of
the Rosetta team. I look forward to helping the company further establish
its leadership position in the field of microRNAs and to advancing the
technology platform across both the diagnostic and therapeutic sectors."
Prior to joining Sirna, Mr. French was the Chief Business Officer at
Entelos, Inc where he was responsible for business development, alliance
management and corporate communication activities helping to expand
Entelos' business from technology-based research partnerships to
therapeutic focused co-development collaborations. Earlier in his career,
he developed global strategic alliances for Farma Biagini S.p.A. and helped
successfully launch Kogenate(R) (a recombinant Factor VIII product) for
Bayer AG. Mr. French is a former U.S. Army officer who served as the Senior
Medical Intelligence Analyst during Operation Desert
Storm. Among his military decorations are the Bronze Star Medal and
Defense Meritorious Service Medal. Mr. French holds a B.S. in aerospace
engineering from the U.S. Military Academy at West Point and a M.S. in
physiology and biophysics from Georgetown University.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of
microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
integrative research platform combining bioinformatics and state-of-the-art
laboratory processes has led to the discovery of hundreds of biologically
validated novel human microRNAs. Building on its strong IP position and
strategic alliances with leading biotechnology companies, Rosetta Genomics
is working to develop a full range of diagnostic and therapeutic products
based on microRNAs. The company's primary focus is in the development of
microRNA-based products to diagnose and treat different forms of cancer and
Media & Investors
SOURCE Rosetta Genomics Ltd